

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2007

THE COOPER COMPANIES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

1-8597
(Commission File Number)

94-2657368
(IRS Employer
Identification No.)

6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588
(Address of principal executive offices)

(925) 460-3600
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure.

On November 14, 2007, The Cooper Companies, Inc. plans to make a Company presentation at a health care conference that includes additional non-public information. The presentation includes revenue guidance for fiscal 2008 at page 18. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report and shall not be deemed "filed" under the Securities Exchange Act of 1934, as amended.

Internet addresses in the release are for information purposes only and are not intended to be hyperlinks to other The Cooper Companies, Inc. information.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Company presentation dated November 14, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE COOPER COMPANIES, INC.

By /s/ Carol R. Kaufman
Carol R. Kaufman
Senior Vice President of Legal Affairs,
Secretary and Chief Administrative Officer

Dated: November 14, 2007

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>	<u>Sequentially Numbered Page</u>
99.1	Company presentation dated November 14, 2007	



NYSE: COO

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking projections of Cooper's results. Actual results could differ materially from these projections. Additional information concerning factors that could cause material differences can be found in Cooper's periodic filings with the Securities and Exchange Commission. They are available publicly and on request from Cooper's investor relations department.

THE COMPANY

Medical devices

- Vision care
- Women's healthcare

Market leadership

Favorable demographics

Consistent long-term performance

CONSISTENT PERFORMANCE (CAGR Ex Call Outs)

	<u>2001- 2006 5 Year CGR</u>
Revenue	30%
Operating Income	26%
EPS - Continuing Operations	17%

COO BUSINESS GOALS

Low to mid-teens revenue growth for next five years

- **CVI double digit**
- **CSI high-teens, including M&A**

Earnings growth mid-teens to high-teens

COO BUSINESS GOALS

CooperVision


- Grow 1.5 times worldwide market next 5 years
- Largest specialty lens company
- Move to #2 position worldwide
- Operating margin mid to upper 20's

COO BUSINESS GOALS

CooperSurgical

- Revenue of \$300M by 2011 including acquisitions
- Operating margin in mid 20's

CooperVision



CooperVision®

SEE BEYOND THE ORDINARY®

MARKET SEGMENTS

(worldwide, millions of \$'s)

	<u>2006</u>	<u>2011</u>	<u>CGR</u>
Daily Disposable Spheres	\$1,459	\$2,505	11%
All Other Spheres	\$2,082	\$2,555	4%
Specialty	\$1,191	\$1,718	8%
Total Market	\$4,732	\$6,778	7%

GEOGRAPHIC MARKET SEGMENTS

(millions of \$'s)	<u>2006</u>	<u>2011</u>	<u>CGR</u>
Americas	\$1,964	\$2,665	6%
Europe*	\$1,328	\$1,559	3%
Asia/Pacific	\$1,440	\$2,555	12%
Total Market	\$4,732	\$6,778	7%

*Includes Mideast and Africa

Source: company reported data and independent market audit

WORLD MARKET DRIVERS

- Growing indication: myopia
- Favorable demographics: teens
- Specialty and value-added vs. commodity: improved lens technology
- Geographic expansion

COOPERVISION TODAY

- \$800M in 2007 vs. \$38M in 1994
- #2 in Europe; #2 in US; #3 worldwide
- Specialty lenses
- Worldwide toric lens market leader

Contact Lens Global Market*

% change and % share

	<u>Q307</u>	<u>CVI</u>	<u>YTD07</u>	<u>CVI</u>
Single Use	+10 33	+31 16	+12 32	+29 14
Reusable Sphere	n/c 42	-2 42	n/c 43	-2 43
Specialty	+6 25	+6 42	+6 25	+5 43
Total	+5 100	+6 100	+5 100	+5 100

*Independent audit data

Contact Lens Global Market*

US versus ROW

	<u>YTD07</u>	<u>%US</u>	<u>YTD07</u>	<u>%ROW</u>
Single Use	+2	10% (+2)	+10	45% (+2)
Reusable Sphere	+2	57% (-2)	-2	33% (-3)
Specialty	+3	33% (n/c)	+8	22% (+1)
Total	+5	100%	+5	100%

*Independent audit data

Contact Lens Global Market*

% change

	<u>Q307</u>	<u>CVI</u>	<u>YTD07</u>	<u>CVI</u>
United States	+4	+6	+5	+2
Europe	+1	+4	n/c	+4
Asia	+10	+21	+10	+21
Total	+5	+6	+5	+5

*Independent audit data

Contact Lens Global Market*

Q307 versus Q207

	<u>MKT</u>	<u>CVI</u>
United States	-2	+7
Europe	n/c	n/c
Asia	+4	+5
Total	+n/c	+5

*Independent audit data

Contact Lens Global Market*

Competitive Landscape

% change

	<u>Q3</u>	<u>YTD</u>
JNJ (43%)	+14	+15
COO (17%)	+6	+5
Others (40%)	-11	-5
Total (100%)	+5	+5

*Independent audit data

Revenue Guidance

(\$Millions)

	<u>2007*</u>	<u>2008</u>
CVI	\$790 - \$810	\$855 - \$920
CSI	\$150 - \$157	\$165 - \$170
TOTAL	\$940 - \$967	\$1,020 - \$1,090

*as issued on 9/6/07

UPDATES

- Manufacturing capacity
- New Products
 - 2 week silicone hydrogel
 - Silicone hydrogel toric
 - *Proclear* daily disposable in Japan



WOMEN'S HEALTHCARE

WOMEN'S HEALTHCARE

- Favorable demographics
- Pharma, capital equipment, in-office
- Fragmented market
- Changing market dynamics

COOPERSURGICAL STRATEGY

- Consolidate market
- New in-office product opportunities
- Fertility and hospital procedures
- Disposable/reusable components

PROCEDURES

- Cervical disease
- Incontinence
- Infertility
- Osteoporosis (diagnostic)
- Menstrual disorders
- Menopause
- Birth control

COOPERSURGICAL TODAY

- **\$125M FY 2006**
- **Consumables 85%; capital equipment 15%**
- **In-office market segment leader**
- **Recent acquisitions**
- **U.S. 85%**

CSI OBJECTIVES

- \$125M 2006 – \$300M 2011
- 25% operating margin
- Expand in hospital segment
- 20% ROI M&A hurdle
- Accelerate organic growth
- Expand geographically



NYSE:COO

Financial Highlights

CAPITAL STRUCTURE 7-31-07

(\$'s in Millions)

Total Debt		\$861
Stockholders' Equity		\$1435
Total Capitalization		\$2297
Total Debt /Capitalization	38%	


COO CONSOLIDATED REVENUE

(\$ in millions)




CONSOLIDATED OPERATING INCOME (Ex Call Outs)

(\$ in millions)



CVI CONSOLIDATED OPERATING INCOME (Ex Call Outs)

(\$ in millions)



CSI CONSOLIDATED OPERATING INCOME (Ex Call Outs)

(\$ in millions)



TAXES


- **Net Operating Loss
Carryforwards \$143 million**
- **Global Tax Arrangement**
- **Effective Tax Rates**

CASH FLOW FROM OPERATING ACTIVITIES

(\$ in millions)



HISTORY OF SUCCESSFUL DELEVERAGING





NYSE: COO

